Evidence map›Paper›PMID 32552305›Full record

ReviewCancer biology & therapy2020

Third-line sunitinib treatment in a

Xiaofen Li, Limin Gao, Li Zhang, Hongna Sun, Hongfeng Gou

Open access · bronzeAbstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancer biology & therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Xiaofen LiDepartment of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, P.R. China.ORCID 0000-0002-1064-768X
Limin GaoDepartment of Pathology, West China Hospital, Sichuan University, Chengdu, P.R. China.
Li ZhangDepartment of Oncology, Pengzhou People's Hospital, Pengzhou, P.R. China.
Hongna SunDepartment of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, P.R. China.
Hongfeng GouDepartment of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, P.R. China.
Sichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intrahepatic cholangiocarcinoma (iCCA) is a highly aggressive malignancy with a poor prognosis. There is no standard treatment beyond first-line chemotherapy and no molecular-targeted drug approved for advanced iCCA. We herein present a case of a 46-y-old Asian iCCA patient with multiple metastases in lung, bone, and liver. The patient progressed rapidly after first- and second-line chemotherapy. According to next-generation sequencing result of somatic Von Hippel-Lindau (

Indexed as

Antineoplastic AgentsCholangiocarcinomaFemaleHumansMiddle AgedSunitinibVon Hippel-Lindau Tumor Suppressor ProteinAntineoplastic AgentsSunitinibVHL protein, humanVon Hippel-Lindau Tumor Suppressor Proteincase reportMetastatic cholangiocarcinomanext-generation sequencingsunitinibVHL gene

Identifiers

PMID32552305
PMCPMC7515542
OpenAlexW3036405787

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.